H. Lijnen

发表

Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.

L. Nelles, C. Kluft, H. K. Nieuwenhuis, 1987, Science.

Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.

D. Collen, M. Dewerchin, K. Okada, 1999, Blood.

Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis

D. Collen, H. Lijnen, 1989 .

Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).

L. Nelles, D. Collen, W. Holmes, 1987, The Journal of biological chemistry.

Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.

D. Collen, W. Holmes, H. Lijnen, 1987, Biochemistry.

On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.

B. Wiman, D. Collen, H. Lijnen, 1979, Biochimica et biophysica acta.

Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein.

M. Hoylaerts, D. Collen, H. Lijnen, 1980, The Journal of biological chemistry.

Basic and clinical aspects of fibrinolysis and thrombolysis.

D. Collen, H. Lijnen, 1991, Blood.

Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity

P. Dutar, J. Billard, D. Vivien, 2012, Cell Death and Differentiation.

Properties of staphylokinase and its potential as a thrombolytic agent

D. Collen, H. Lijnen, S. Vanderschueren, 1995 .

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993 .

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993, Blood.

Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies.

D. Collen, P. Holvoet, H. Lijnen, 1986, European journal of biochemistry.

Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.

D. Collen, H. Lijnen, D. Stump, 1986, The Journal of biological chemistry.

Fibrin‐specific Fibrinolysis

D. Collen, H. Lijnen, D. Collen, 1992, Annals of the New York Academy of Sciences.

Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin.

D. Collen, H. Lijnen, F. de Cock, 1979, European journal of biochemistry.

Structural domains of streptokinase involved in the interaction with plasminogen.

M. Barro, D. Collen, H. Lijnen, 1995, European journal of biochemistry.

Histidine-rich glycoprotein in a normal and a clinical population.

D. Collen, H. Lijnen, G. Jacobs, 1981, Thrombosis research.

Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy.

D. Collen, H. Lijnen, F. Decock, 1981, Thrombosis research.

Turnover of histidine-rich glycoprotein during heparin administration in man.

D. Collen, H. Lijnen, 1983, Thrombosis research.

Histidine-Rich Glycoprotein Modulates the Anticoagulant Activity of Heparin in Human Plasma

D. Collen, H. Lijnen, B. van Hoef, 1984, Thrombosis and Haemostasis.

Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.

D. Collen, H. Lijnen, B. van Hoef, 1986, Biochimica et biophysica acta.

Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures.

D. Collen, H. Lijnen, D. Stump, 1986, The Journal of biological chemistry.

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

M. Hoylaerts, D. Collen, H. Lijnen, 1982, The Journal of biological chemistry.

Strategies for the Improvement of Thrombolytic Agents

D. Collen, H. Lijnen, 1991, Thrombosis and Haemostasis.

Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.

H. Lijnen, M. Verstraete, D. Collen, 1986, Circulation.

Tissue-type plasminogen activator: helping patients with acute myocardial infarction

D. Collen, H. Lijnen, H. Lijnen, 2001 .

Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

P. Carmeliet, D. Collen, N. Nagai, 1999, Circulation.

Interactions between Staphylokinase, Plasmin(ogen), and Fibrin

H. Lijnen, D. Rijken, D. V. Sakharov, 1996, The Journal of Biological Chemistry.

Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species

D. Collen, H. Lijnen, E. Demarsin, 1984, Thrombosis and Haemostasis.

Recent developments in thrombolytic therapy

D. Collen, H. Lijnen, 2000 .

Characterization and Targeting of the Murine α2-Antiplasmin Gene

M. Dewerchin, R. Lijnen, A. Belayew, 1997, Thrombosis and Haemostasis.

Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.

M. Dewerchin, K. Okada, O. Matsuo, 1999, Blood.

Matrix Metalloproteinases and Cellular Fibrinolytic Activity

H. Lijnen, 2004, Biochemistry (Moscow).

Effects of plasminogen activator inhibitor‐1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice

N. Nagai, D. Collen, H. Lijnen, 2005, Journal of thrombosis and haemostasis : JTH.

Amidolytic determination of Factor X in clinical plasma samples.

D. Collen, H. Lijnen, P. Robijns, 1983, Acta Clinica Belgica.

Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog

B. Keyt, H. Gold, T. Roskams, 1994, Thrombosis and Haemostasis.

Role of placental growth factor in glucose metabolism

H. Lijnen, G. Voros, 2006, Journal of thrombosis and haemostasis : JTH.

Macrophage elastase (MMP-12) in expanding murine adipose tissue.

D. Bauters, H. Lijnen, M. Van Hul, 2013, Biochimica et biophysica acta.

Role of Thrombospondin‐2 in Murine Adipose Tissue Angiogenesis and Development

H. Lijnen, M. Hul, L. Frederix, 2012, Obesity.

Influence of membrane‐bound tumor necrosis factor (TNF)‐α on obesity and glucose metabolism

D. Collen, H. Lijnen, E. Maquoi, 2004, Journal of thrombosis and haemostasis : JTH.

Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.

D. Collen, H. Lijnen, E. Maquoi, 2003, Biochimica et biophysica acta.

Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers

T. van der Poll, P. Bresser, A. D. de Vos, 2005, Thrombosis and Haemostasis.

Deficiency of Bmal1 disrupts the diurnal rhythm of haemostasis

R. Lijnen, B. Hemmeryckx, H. Lijnen, 2019, Experimental Gerontology.

History of Discovery The Tissue-Type Plasminogen Activator Story

D. Collen, H. Lijnen, 2009 .

The tissue-type plasminogen activator story.

D. Collen, H. Lijnen, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Tissue‐type plasminogen activator: a historical perspective and personal account

D. Collen, H. Lijnen, 2004, Journal of thrombosis and haemostasis : JTH.

On the future of thrombolytic therapy for acute myocardial infarction.

D. Collen, H. Lijnen, 1993, The American journal of cardiology.

Deficiency of thrombospondin‐1 in mice does not affect adipose tissue development

H. Lijnen, H. Lijnen, G. Voros, 2006, Journal of thrombosis and haemostasis : JTH.

Structural and Functional Basis of Plasminogen Activation by Staphylokinase

M. de Maeyer, L. Jespers, D. Collen, 1999, Thrombosis and Haemostasis.

Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology

D. Collen, H. Lijnen, B. van Hoef, 1984, Thrombosis and Haemostasis.

Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys

D. Collen, H. Lijnen, F. De Cock, 1984, Thrombosis and Haemostasis.

Adipose Tissue and Atherothrombosis

D. Bastelica, M. Alessi, H. Lijnen, 2003, Pathophysiology of Haemostasis and Thrombosis.

Haemostasis

J. Arnout, H. Lijnen, M. Hoylaerts, 2013, Methods in Molecular Biology.

Pathophysiology of the plasminogen/plasmin system

H. Lijnen, 1996, International journal of clinical & laboratory research.

The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury

P. Carmeliet, T. van der Poll, V. de Waard, 2005, Journal of thrombosis and haemostasis : JTH.

On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice

D. Collen, H. Lijnen, I. Juhan-vague, 2005, Journal of thrombosis and haemostasis : JTH.

Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis1

T. van der Poll, A. D. de Vos, S. Florquin, 2006, The Journal of Immunology.

Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia coli-Induced Abdominal Sepsis in Mice1

P. Carmeliet, T. van der Poll, A. D. de Vos, 2006, The Journal of Immunology.

Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor.

J. Verhaeghe, B. Hemmeryckx, L. Vercruysse, 2008, Endocrinology.

Obesity promotes injury induced femoral artery thrombosis in mice.

M. Hoylaerts, N. Nagai, B. V. van Vlijmen, 2008, Thrombosis research.

Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet.

H. Lijnen, 2006, Thrombosis research.

Screening panels of monoclonal antibodies using phage-displayed antigen.

I. Lasters, L. Jespers, D. Collen, 1997, Analytical biochemistry.

A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induces a modification of its functional properties

J. Soria, C. Soria, O. Bertrand, 1997 .

Functional interactions between pancreatic beta cells and (pre)adipocytes

Valerie Christiaens, V. Christiaens, D. Pipeleers, 2010, Endocrine.

Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases.

D. Collen, H. Lijnen, F. De Cock, 1980, Biochimica et biophysica acta.

Increased Angiostatin Levels in Bronchoalveolar Lavage Fluids from ARDS Patients and from Human Volunteers after Lung Instillation of Endotoxin

K. Steinberg, T. Martin, R. Lucas, 2002, Thrombosis and Haemostasis.

Towards better thrombolytic therapy.

H. Gold, D. Collen, H. Lijnen, 1991, Progress in cardiovascular diseases.

Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.

J. Schneider, G. Steffens, D. Collen, 1995, European journal of biochemistry.

Correlation between Progressive Adsorption of Plasminogen to Blood Clots and Their Sensitivity to Lysis

D. Keber, M. Šabovič, D. Collen, 1990, Thrombosis and Haemostasis.

Impaired fibrinolysis and the risk for coronary heart disease.

D. Collen, H. Lijnen, 1996, Circulation.

Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis

D. Collen, H. Lijnen, J. Stassen, 1991 .

Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.

M. Hoylaerts, D. Collen, H. Lijnen, 1983, The Journal of biological chemistry.

Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.

D. Collen, H. Lijnen, F. De Cock, 1994, European journal of biochemistry.

Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

K. Goa, D. Collen, H. Lijnen, 1989, Drugs.

Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.

D. Collen, H. Lijnen, C. Zamarrón, 1984, Thrombosis research.

Plasminogen activator inhibitor‐1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice

H. Lijnen, N. Nagai, H. Lijnen, 2007, Journal of thrombosis and haemostasis : JTH.

Amino‐acid sequence of human α2‐antiplasmin

B. Wiman, D. Collen, H. Lijnen, 1987 .

Amino-acid sequence of human a2-antiplasmin

B. Wiman, H. Lijnen, D. Collen, 1987 .

The fibrinolytic system in man.

E. Plow, D. Collen, H. Lijnen, 1986, Critical reviews in oncology/hematology.

Chapter 8 Fibrinolysis and thrombolysis

D. Collen, H. Lijnen, 1986 .

New approaches to thrombolytic therapy.

D. Collen, H. Lijnen, 1984, Arteriosclerosis.

Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro

O. Matsuo, D. Collen, H. Lijnen, 1992 .

Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?

D. Collen, H. Lijnen, 1994, Blood.

The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.

D. Collen, H. Lijnen, B. van Hoef, 1989, Blood.

Role of Active Center and Lysine Binding Sites of Plasmin in Plasmin-Induced Platelet Activation and Disaggregation

Hong Li, J. Soria, C. Soria, 1991, Thrombosis and Haemostasis.

New strategies in the development of thrombolytic agents.

D. Collen, H. Lijnen, 1988, Blut.

Effect of Standard and Low-Molecular Weight Heparin Fractions on Fibrinolysis and Platelet Aggregation in Patients Undergoing Hysterectomy

M. Verstraete, H. Lijnen, H. Bounameaux, 1986, Thrombosis and Haemostasis.

Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator.

D. Collen, H. Lijnen, 1986, Thrombosis research.

Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development

J. Vermylen, M. Dewerchin, M. Hoylaerts, 2001, Circulation research.

Remaining Perspectives of Mutant and Chimeric Plasminogen Activators

D. Collen, H. Lijnen, 1992, Annals of the New York Academy of Sciences.

Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.

T. Quertermous, M. Dewerchin, M. Ginsberg, 1991, Blood.

Role of plasminogen activation in neuronal organization and survival

J. Corsi, H. Enslen, E. Angles-cano, 2009, Molecular and Cellular Neuroscience.

Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.

M. Dewerchin, M. Hoylaerts, H. Lijnen, 2000, Blood.

Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems

H. Lijnen, 2000 .

Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

R. Colman, M. Schapira, H. Lijnen, 1984, The Journal of clinical investigation.

Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1991, The Journal of biological chemistry.

Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.

M. Dewerchin, D. Collen, H. Lijnen, 1990, Thrombosis research.

Characterisation of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising Leu144 through Leu411) and F(ab′)2-fragments of a fibrin D-dimer-specific monoclonal antibody

M. Dewerchin, D. Collen, H. Lijnen, 1990 .

Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.

M. Dewerchin, D. Collen, H. Lijnen, 1989, European journal of biochemistry.

Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.

R. Lijnen, D. Collen, H. Lijnen, 1984, The Journal of biological chemistry.

Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.

H. Lijnen, D. Collen, H. Lijnen, 1992, Journal of the American College of Cardiology.

Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators

L. Nelles, H. Lijnen, D. Collen, 1991, Circulation.

Activation of plasminogen by pro-urokinase. II. Kinetics.

M. Hoylaerts, D. Collen, H. Lijnen, 1986, The Journal of biological chemistry.

infusion activator to fibrin: useful to monitor fibrinogen breakdown during t-PA A monoclonal antibody preventing binding of tissue-type plasminogen

D. Collen, P. Holvoet, H. Lijnen, 2011 .

New strategies in the development of thrombolytic agents

D. Collen, H. Lijnen, 1988, Blut.

mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 )

L. Nelles, D. Collen, H. Lijnen, 2003 .

Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.

L. Nelles, D. Collen, H. Lijnen, 1992, Blood.

A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion.

D. Collen, P. Holvoet, H. Lijnen, 1986, Blood.

Characterisation of a mutant of recombinant human single chain urokinase-type plasminogen activator (scu-PA), obtained by substitution of arginine 156 and lysine 158 with threonine

D. Collen, H. Lijnen, A. Bollen, 1988 .

Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury.

K. Rouschop, W. Frederiks, S. Florquin, 2005, Journal of the American Society of Nephrology : JASN.

This information is current as-Induced Abdominal Sepsis in Mice coli Escherichia Activator Is Protective during Endogenous Tissue-Type Plasminogen

P. Carmeliet, T. Poll, S. Florquin, 2006 .

Tissue-type plasminogen activator, a new prognostic marker in breast cancer.

M. Duffy, J. Fennelly, H. Lijnen, 1988, Cancer research.

Molecular mechanisms of thrombolysis: implications for therapy.

D. Collen, H. Lijnen, 1990, Biochemical pharmacology.

Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro

D. Collen, H. Lijnen, E. Demarsin, 1986, Thrombosis and Haemostasis.

Effect of gelatinase inhibition on adipogenesis and adipose tissue development

U. Himmelreich, D. Bauters, H. Lijnen, 2012, Clinical and experimental pharmacology & physiology.

A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.

M. Cuzner, D. Baker, G. Pryce, 2005, The American journal of pathology.

Endothelium in hemostasis and thrombosis.

D. Collen, H. Lijnen, D. Collen, 1997, Progress in cardiovascular diseases.

Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).

D. Collen, H. Lijnen, B. van Hoef, 1998, Biochemistry.

J . Silence , F . Lupu , D . Collen and H . R . Lijnen Stromelysin-1 ( MMP-3 ) Gene Inactivation Persistence of Atherosclerotic Plaque but Reduced

F. Lupu, D. Collen, H. Lijnen, 2001 .

Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura

H. Deckmyn, F. Peyvandi, R. Palla, 2010, Journal of thrombosis and haemostasis : JTH.

Enzymatic properties of phage-displayed fragments of human plasminogen.

I. Lasters, L. Jespers, D. Collen, 1997, European journal of biochemistry.

Interactions of Staphylokinase with Human Platelets

D. Collen, H. Lijnen, B. van Hoef, 1995, Thrombosis and Haemostasis.

On the mechanism of fibrin-specific plasminogen activation by staphylokinase.

K. Okada, O. Matsuo, D. Collen, 1991, The Journal of biological chemistry.

Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis 1

S. Florquin, J. Roelofs, C. Veer, 2006 .

Mechanisms of plasminogen activation by mammalian plasminogen activators.

D. Collen, H. Lijnen, 1988, Enzyme.

Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis

K. Okada, O. Matsuo, D. Collen, 1991, Thrombosis and Haemostasis.

Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques

A. Luttun, P. Carmeliet, D. Collen, 2006, Journal of thrombosis and haemostasis : JTH.

Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen

P. Carmeliet, L. Moons, D. Collen, 1996 .

Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.

K. Silence, D. Collen, H. Lijnen, 1993, Blood.

Biochemical-properties of natural and recombinant staphylokinase

D. Collen, H. Lijnen, B. Hoef, 1992 .

On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin

O. Matsuo, D. Collen, H. Lijnen, 1992 .

Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.

L. Nelles, D. Collen, H. Lijnen, 1990, The Journal of biological chemistry.

A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis.

D. Collen, P. Holvoet, H. Lijnen, 1986, European journal of biochemistry.

Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator.

J. Soria, C. Soria, H. Lijnen, 1984, Thrombosis research.

Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase.

D. Collen, H. Lijnen, B. van Hoef, 1984, European journal of biochemistry.

Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin

D. Collen, H. Lijnen, Ph.D H.R. LIJNEN, 1982, Seminars in thrombosis and hemostasis.

Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties.

D. Collen, H. Lijnen, 1986, Haemostasis.

Age-associated adaptations in murine adipose tissues.

D. Loeckx, T. Dresselaers, U. Himmelreich, 2010, Endocrine journal.

Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis*

B. Schlott, K. Silence, D. Collen, 1996 .

Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.

B. Schlott, D. Collen, H. Lijnen, 1994, Biochimica et biophysica acta.

Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.

L. Nelles, D. Collen, H. Lijnen, 1992, Biochimica et biophysica acta.

Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-12 of α2-antiplasmin (fibrin cross-linking site) and amino aids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator

H. Nakamura, D. Collen, H. Lijnen, 1992 .

Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.

L. Nelles, D. Collen, H. Lijnen, 1992, European journal of biochemistry.

Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.

D. Collen, H. Lijnen, J. Stassen, 1991, Blood.

Small Animal Thrombosis Models for the Evaluation of Thrombolytic Agents

L. Kieckens, D. Collen, J. Stassen, 1991, Circulation.

Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.

L. Nelles, A. Vandamme, A. Tulinsky, 1990, The Journal of biological chemistry.

Effect of Retraction on the Lysis of Human Clots with Fibrin Specific and Non-Fibrin Specific Plasminogen Activators

D. Keber, M. Šabovič, D. Collen, 1989, Thrombosis and Haemostasis.

Interaction of Heparin with Histidine-Rich Glycoprotein and with Antithrombin III

D. Collen, H. Lijnen, B. van Hoef, 1983, Thrombosis and Haemostasis.

Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase

A. Vandamme, M. Dewerchin, P. Holvoet, 1992, Thrombosis and Haemostasis.

Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.

L. Nelles, A. Vandamme, M. Dewerchin, 1992, European journal of biochemistry.

plasma clot lysis with single-chain urokinase-type plasminogen activator in plasminogen activator. Application to the study of the mechanism of A monoclonal antibody specific for two-chain urokinase-type

P. Declerck, H. Moreau, D. Collen, 2011 .

A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.

P. Declerck, H. Moreau, D. Collen, 1990, Blood.

On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.

D. Collen, H. Lijnen, B. van Hoef, 1991, The Journal of biological chemistry.

Dysfibrinogenemia (Fibrinogen Dusard) Associated with Impaired Fibrin-Enhanced Plasminogen Activation

J. Soria, C. Soria, D. Collen, 1984, Thrombosis and Haemostasis.

Chapter 6 Explanations for coagulation activation after air travel

S. Middeldorp, H. Lijnen, J. Meijers, 2009 .

Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin.

D. Collen, H. Lijnen, 1981, Thrombosis research.

The reaction of azide with Limulus polyphemus methaemocyanin

H. Lijnen, R. Witters, R. Lontie, 1978, FEBS letters.

TOWARDS THE DEVELOPMENT OF IMPKOVED THROMBOLYTIC AGENTS

D. Collen, H. Lijnen, 1991, British journal of haematology.

Activation of plasminogen by pro-urokinase. I. Mechanism.

M. Blaber, D. Collen, H. Lijnen, 1986, The Journal of biological chemistry.

In Vitro Fibrinolytic Activity of Recombinant Tissue-Type Plasminogen Activator in the Plasma of Various Primate Species

D. Collen, H. Lijnen, B. Marafino, 1984, Thrombosis and Haemostasis.

Fibrinolytic Agents: Mechanisms of Activity and Pharmacology

D. Collen, H. Lijnen, 1995, Thrombosis and Haemostasis.

Neutralization of heparin activity by binding to human histidine-rich glycoprotein.

M. Hoylaerts, D. Collen, H. Lijnen, 1983, Thrombosis research.

Studies on the mechanism of the antifibrinolytic action of tranexamic acid.

M. Hoylaerts, D. Collen, H. Lijnen, 1981, Biochimica et biophysica acta.

Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.

D. Collen, H. Lijnen, C. Zamarrón, 1985, European journal of biochemistry.

Molecular mechanism of fibrinolysis.

D. Collen, H. Lijnen, 1984, Advances in experimental medicine and biology.

Differential Inhibition with Antifibrinolytic Agents of Staphylokinase and Streptokinase Induced Clot Lysis

D. Collen, J. Stassen, H. Lijnen, 1995, Thrombosis and Haemostasis.

Modulation of Cell-associated Plasminogen Activation by Stromelysin-1 (MMP-3)

D. Collen, H. Lijnen, F. Ugwu, 1999, Thrombosis and Haemostasis.

Mechanisms of physiological fibrinolysis.

D. Collen, H. Lijnen, D. Collen, 1995, Bailliere's clinical haematology.

On the role of placental growth factor in murine adipogenesis.

V. Christiaens, I. Scroyen, H. Lijnen, 2007, Thrombosis research.

Impaired Adipose Tissue Development in Mice With Inactivation of Placental Growth Factor Function

P. Carmeliet, V. Christiaens, D. Collen, 2006, Diabetes.

Mechanisms of plasminogen activation

V. Ellis, H. Pannekoek, D. Collen, 1994, Journal of internal medicine.

Staphylokinase, a fibrin-specific bacterial plasminogen activator

D. Collen, H. Lijnen, 1996 .

Characterization of the interaction between plasminogen and staphylokinase.

B. Schlott, D. Collen, H. Lijnen, 1994, European journal of biochemistry.

On the mechanism of the activation of human plasminogen by recombinant staphylokinase.

Y. Engelborghs, B. Schlott, D. Collen, 1993, The Journal of biological chemistry.

Interaction of staphylokinase with different molecular forms of plasminogen.

D. Collen, H. Lijnen, B. van Hoef, 1993, European journal of biochemistry.

Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin‐induced cell detachment and apoptosis

B. Ho-Tin-Noé, H. Lijnen, R. Vranckx, 2005, The FEBS journal.

Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.

H. Lijnen, V. Fleury, E. Anglés-Cano, 1993, The Journal of biological chemistry.

A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo.

D. Collen, P. Holvoet, H. Lijnen, 1985, Journal of Biological Chemistry.

Fibrin-specific Clot Lysis with Single Chain Urokinase-type Plasminogen Activator (scu-PA)

P. Declerck, D. Collen, H. Lijnen, 1990 .

Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activator.

D. Collen, H. Lijnen, B. van Hoef, 1987, European journal of biochemistry.

On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin.

D. Collen, H. Lijnen, B. van Hoef, 1981, European journal of biochemistry.

On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.

D. Collen, H. Lijnen, B. van Hoef, 1990, Thrombosis research. Supplement.

Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor.

D. Rylatt, D. Collen, H. Lijnen, 1983, Biochimica et Biophysica Acta.

The pathophysiological role of fibrinolysis inhibitors

H. Lijnen, D. Collen, H. Lijnen, 1984, La Ricerca in Clinica e in Laboratorio.

Binding of streptokinase and staphylokinase to plasminogen

D. Collen, H. Lijnen, P. Rodríguez, 1995 .

Protease inhibitors of human plasma. Alpha-2-antiplasmin.

D. Collen, H. Lijnen, 1985, Journal of medicine.

Isolation and characterisation of natural and recombinant staphylokinase

K. Silence, D. Collen, H. Lijnen, 1992 .

Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones.

D. Collen, H. Lijnen, M. Uytterhoeven, 1984, Thrombosis Research.

Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy

D. Collen, H. Lijnen, 1995, Thrombosis and Haemostasis.

Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.

P. Verhamme, J. Stassen, H. Lijnen, 2009, Clinical therapeutics.

Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.

D. Collen, H. Lijnen, F. Ugwu, 2001, Thrombosis research.

Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3).

M De Maeyer, M. de Maeyer, Jordi Félez, 2001, European journal of biochemistry.

Development of thrombolytic agents.

D. Collen, H. Lijnen, 1993, Biotechnology advances.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

M. Cuzner, G. Pryce, D. Baker, 1998 .

Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.

L. Nelles, D. Collen, H. Lijnen, 1988, European journal of biochemistry.

Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160

L. Nelles, D. Collen, H. Lijnen, 1990 .

Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.

L. Nelles, D. Collen, W. Holmes, 1988, European journal of biochemistry.

Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.

D. Collen, H. Lijnen, B. van Hoef, 1987, European journal of biochemistry.

Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.

D. Collen, H. Lijnen, A. Bollen, 1987, The Journal of biological chemistry.

Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.

L. Nelles, D. Collen, W. Holmes, 1987, The Journal of biological chemistry.

Single-Chain Urokinase-Type Plasminogen Activator: Mechanism of Action and Thrombolytic Properties

D. Collen, H. Lijnen, D. Stump, 1987, Seminars in thrombosis and hemostasis.

Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin

L. Kieckens, M. Dewerchin, D. Collen, 1989 .

Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).

L. Nelles, D. Collen, H. Lijnen, 1990, The Journal of biological chemistry.

Molecular Regulation of Fibrinolysis

H. Lijnen, 1997 .

Multiple forms of plasminogen activator in human breast tumors.

M. Duffy, H. Lijnen, P. O'grady, 1985, Cancer research.

Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation

F. Lupu, D. Collen, H. Lijnen, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Primary Structure of Human a2-Antiplasmin, a Serine Protease Inhibitor (Serpin)*

L. Nelles, H. Lijnen, W. Holmes, 2001 .

Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface.

M De Maeyer, M. de Maeyer, L. Jespers, 1999, Journal of molecular biology.

A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents

D. Collen, H. Lijnen, J. Stassen, 1990 .

Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11)

M. Rio, D. Collen, H. Lijnen, 1998 .

Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type-1 (TIMP-1)

P. Soloway, D. Collen, H. Lijnen, 1998 .

Characterization of the murine plasma fibrinolytic system.

H. Lijnen, D. Collen, H. Lijnen, 1994, European journal of biochemistry.

Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD

P. Morange, M. Alessi, D. Collen, 2002 .

In vitro prothrombin synthesis from a purified precursor protein. III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin.

H. Hemker, C. Vermeer, H. Lijnen, 1981, Biochimica et biophysica acta.

Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.

B. Schlott, D. Collen, H. Lijnen, 1993, European journal of biochemistry.

therapeutic potential? Staphylokinase, a fibrin-specific plasminogen activator with

D. Collen, H. Lijnen, 2011 .

Bio-Immunoassay for Staphylokinase in Blood

P. Declerck, D. Collen, H. Lijnen, 1993, Thrombosis and Haemostasis.

Functional Properties of p-Anisoylated Plasmin-Staphylokinase Complex

D. Collen, H. Lijnen, B. van Hoef, 1993, Thrombosis and Haemostasis.

Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice

M. Hoylaerts, B. V. van Vlijmen, H. Lijnen, 2009, Thrombosis and Haemostasis.

Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.

D. Rouy, H. Lijnen, E. Anglés-Cano, 1992, Biochimica et biophysica acta.

Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors

B. Wiman, D. Collen, H. Lijnen, 1982, Thrombosis and Haemostasis.

Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin

M. Samama, O. Matsuo, H. Lijnen, 1982, Thrombosis and Haemostasis.

Basic Aspects of Fibrinolysis and Thrombolysis

D. Collen, H. Lijnen, 2002 .

Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.

L. Nelles, D. Collen, W. Holmes, 1988, The Journal of biological chemistry.

Effect of fumagillin on adipocyte differentiation and adipogenesis.

V. Christiaens, I. Scroyen, H. Lijnen, 2010, Biochimica et biophysica acta.

Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors.

M. Duffy, H. Lijnen, P. O'grady, 1986, Journal of the National Cancer Institute.

Effect of premature aging on murine adipose tissue

M. Hoylaerts, B. Hemmeryckx, H. Lijnen, 2012, Experimental Gerontology.

Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.

M. Lauwereys, P. Holvoet, D. Collen, 1992, European journal of biochemistry.

Angiogenesis and development of adipose tissue

V. Christiaens, H. Lijnen, 2010, Molecular and Cellular Endocrinology.

Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene

D. Collen, H. Lijnen, J. Silence, 2002, Circulation research.

Matrix Metalloproteinase System Deficiencies and Matrix Degradation

H. Lijnen, D. Collen, H. Lijnen, 1999, Thrombosis and Haemostasis.

Mouse Genetic Models in Studying Adipose Angiogenesis

I. Scroyen, H. Lijnen, 2013 .

in a hamster pulmonary embolism model continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator Comparative thrombolytic properties of bolus injections and

D. Collen, H. Lijnen, J. Stassen, 2011 .

Characterisation of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site

L. Nelles, D. Collen, H. Lijnen, 1992 .

Biochemical, Thrombolytic and Pharmacokinetic Properties of rt-PA P47G, K49N, a Substitution Variant of Human Tissue-Type Plasminogen Activator

L. Nelles, D. Collen, H. Lijnen, 1992, Thrombosis and Haemostasis.

Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line

D. Collen, H. Lijnen, B. van Hoef, 1992, Thrombosis and Haemostasis.

Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI)

L. Nelles, D. Collen, H. Lijnen, 1990, Thrombosis and Haemostasis.

Effect of Fibrin-Like Stimulators on the Activation of Plasminogen by Tissue-Type Plasminogen Activator (t-PA) - Studies with Active Site Mutagenized Plasminogen and Plasmin Resistant t-PA

R. Lijnen, D. Collen, H. Lijnen, 1990, Thrombosis and Haemostasis.

Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.

L. Pierard, H. Lijnen, M. Reff, 1988, Thrombosis research.

Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH2-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator

L. Nelles, D. Collen, H. Lijnen, 1988, Thrombosis and Haemostasis.

Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

A. Gils, P. Declerck, Christine Vranckx, 2012, Thrombosis research.

Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.

A. Gils, P. Declerck, I. Scroyen, 2011, Thrombosis research.

Tissue-type Plasminogen Activator (tPA) Interacts with Urokinase-type Plasminogen Activator (uPA) via tPA's Lysine Binding Site

H. Lijnen, L. Medved, K. Ingham, 1995, The Journal of Biological Chemistry.

Biochemical and biological properties of single-chain urokinase-type plasminogen activator.

D. Collen, H. Lijnen, D. Stump, 1986, Cold Spring Harbor Symposia on Quantitative Biology.

Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.

L. Nelles, D. Collen, H. Lijnen, 1988, The Journal of biological chemistry.

Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.

L. Nelles, D. Collen, W. Holmes, 1987, The Journal of biological chemistry.

Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface.

W. Nieuwenhuizen, H. Lijnen, V. Fleury, 1993, European journal of biochemistry.

Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma

P. Declerck, D. Collen, H. Lijnen, 1991, Thrombosis and Haemostasis.

Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model

L. Nelles, L. Kieckens, D. Collen, 1991, Thrombosis and Haemostasis.

Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin

D. Collen, H. Lijnen, D. Rijken, 1981, Thrombosis and Haemostasis.

Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments

D. Collen, H. Lijnen, 1991 .

Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons

D. Collen, H. Lijnen, J. Stassen, 1992 .

D. Collen, H. Lijnen, J. Stassen, 1992, Blood.

Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.

M. Dewerchin, D. Collen, H. Lijnen, 1990, Circulation.

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.

P. Declerck, K. Silence, D. Collen, 1996, Circulation.

Molecular interactions between tissue-type plasminogen activator and plasminogen.

D. Collen, H. Lijnen, 1993, Methods in enzymology.

Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific Monoclonal Antibody Directed against Human Fibrin and against Urokinase-Type Plasminogen Activator

A. Kakinuma, D. Collen, J. Stassen, 1991, Thrombosis and Haemostasis.

Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis

P. Verhamme, F. Werf, J. Stassen, 2010, Journal of Thrombosis and Thrombolysis.

Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma

K. Silence, D. Collen, H. Lijnen, 1993, Thrombosis and Haemostasis.

Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)

M. Blombäck, C. Francis, B. Dahlbäck, 1994, Thrombosis and Haemostasis.

Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1)

D. Collen, H. Lijnen, B. van Hoef, 2004, Journal of thrombosis and haemostasis : JTH.

α2-Antiplasmin Gene Deficiency in Mice Does Not Affect Neointima Formation After Vascular Injury

D. Collen, M. Dewerchin, H. Lijnen, 2000 .

Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin.

K. Silence, D. Collen, H. Lijnen, 1993, The Journal of biological chemistry.

Effect of matrix metalloproteinase inhibition on adipose tissue development.

D. Collen, H. Lijnen, D. Demeulemeester, 2005, Biochemical and biophysical research communications.

Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity

P. Morange, D. Bastelica, H. Lijnen, 2002, Thrombosis and Haemostasis.

Enhanced Fibrinolytic Potential in Mice with Combined Homozygous Deficiency of α2-antiplasmin and PAI-1

M. Dewerchin, D. Collen, H. Lijnen, 2001, Thrombosis and Haemostasis.

Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue

V. Christiaens, H. Lijnen, 2006, Archives of physiology and biochemistry.

Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.

N. Nagai, H. Lijnen, K. Umemura, 2009, Blood.

Vascular and cellular proteolytic activity in mice with α2-antiplasmin gene inactivation

M. Dewerchin, D. Collen, H. Lijnen, 2000 .

PROTEINASE INHIBITORS | Alpha-2 Antiplasmin

H. Lijnen, 2006 .

Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment.

D. Collen, H. Lijnen, 1989, Biotechnology therapeutics.

Fibrin(ogen) degradation by a 24k-endopeptidase from a Chryseobacterium Sp.

I. Roelants, D. Collen, H. Lijnen, 2000 .

Procoagulant Properties of Intravenous Staphylokinase Versus Tissue-Type Plasminogen Activator

H. Moreau, K. Okada, D. Collen, 1996, Thrombosis and Haemostasis.

Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin

M. Dewerchin, D. Collen, H. Lijnen, 1990 .

Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. Introduction.

K. Reid, K. F. Nolan, D. Collen, 1993, Methods in enzymology.

Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.

I. Lasters, M. de Maeyer, L. Jespers, 1998, Biochemistry.

Plasminogen Binding Properties of Macrophage Inflammatory Protein (MIP)-2α

Jordi Félez, D. Collen, H. Lijnen, 2000, Thrombosis and Haemostasis.

The plasminogen‐activation system in ovarian tumors

J. Soria, C. Soria, He Lu, 1993, International journal of cancer.

Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice

T. Dresselaers, J. Buyse, F. Lupu, 2012, Clinical and experimental pharmacology & physiology.

Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator.

M F Hoylaerts, Jordi Félez, M. Hoylaerts, 2000, European journal of biochemistry.

Chronic plasminogen activator inhibitor‐1 (PAI‐1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung

M. Poggi, D. Bastelica, M. Alessi, 2007, Journal of thrombosis and haemostasis : JTH.

Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.

D. Collen, H. Lijnen, E. Maquoi, 2003, Biochimica et biophysica acta.

Deficiency of plasminogen activator inhibitor‐2 impairs nutritionally induced murine adipose tissue development

I. Scroyen, H. Lijnen, H. Lijnen, 2007, Journal of thrombosis and haemostasis : JTH.

No functional role of plasminogen activator inhibitor‐1 in murine adipogenesis or adipocyte differentiation

V. Christiaens, I. Scroyen, H. Lijnen, 2007, Journal of thrombosis and haemostasis : JTH.

New insights into the molecular mechanisms of the fibrinolytic system

H. Lijnen, H. Lijnen, D. Rijken, 2009, Journal of thrombosis and haemostasis : JTH.

Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.

D. Collen, H. Lijnen, S. Vanderschueren, 1995, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

Effect of Vioxx on adipose tissue development in mice with genetically determined obesity

H. Lijnen, 2008, Thrombosis and Haemostasis.

Stromelysin‐1 (MMP‐3) is critical for intracranial bleeding after t‐PA treatment of stroke in mice

H. Lijnen, N. Nagai, D. Collen, 2007, Journal of thrombosis and haemostasis : JTH.

Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin.

B. Wiman, D. Collen, H. Lijnen, 1985, Thrombosis research.

Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.

H. Lijnen, D. Collen, H. Lijnen, 2001, Thrombosis research.

Kinetics of the Inhibition of Plasmin in Acidified Human Plasma

D. Collen, M. Maes, H. Lijnen, 1982, Thrombosis and Haemostasis.

Scientific and Standardization Committee Communications Recommendations for the Nomenclature of Mutant Fibrinolytic Genes and Their Proteins

D. Loskutoff, H. Pannekoek, H. Lijnen, 1990, Thrombosis and Haemostasis.

Plasmin-lnduced Platelet Activation and Disaggregation

Hong Li, He Lu, J. Perrot, 2018 .

A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations

S. Kojima, H. Lijnen, S. Smyth, 2007, Journal of thrombosis and haemostasis : JTH.

Combination of animal models and biotechnologies in the development of new thrombolytic agents

D. Collen, H. Lijnen, J. Stassen, 1993 .